Racial/ethnic disparities in medication use among veterans with hypertension and dementia: A national cohort study

Annals of Pharmacotherapy

Volumn 43, Issue 2, 2009, Pages 185-193

  Poon, Ivy ^a,b,c   Lal, Lincy S ^d   Ford, Marvella E ^e   Braun, Ursula K ^b,c  

^a TEXAS SOUTHERN UNIVERSITY   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d Drug Use Policy and Pharmacoeconomics   (United States)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Aged; Dementia; Drug utilization; Ethnic groups; Hypertension; Race

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FELODIPINE; LOOP DIURETIC AGENT; MEMANTINE; NICARDIPINE; NIFEDIPINE; NISOLDIPINE; NOOTROPIC AGENT; POTASSIUM SPARING DIURETIC AGENT; THIAZIDE DIURETIC AGENT; VERAPAMIL;

AFRICAN AMERICAN; AGED; ARTICLE; CEREBROVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DEMENTIA; DIABETES MELLITUS; DRUG USE; ETHNIC DIFFERENCE; ETHNICITY; FEMALE; HEALTH CARE MANAGEMENT; HEALTH CARE UTILIZATION; HEART FAILURE; HISPANIC; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RACE DIFFERENCE; RETROSPECTIVE STUDY; VETERAN;

AFRICAN AMERICANS; AGED; ANTIHYPERTENSIVE AGENTS; CHOLINESTERASE INHIBITORS; COHORT STUDIES; DEMENTIA; DRUG UTILIZATION; ETHNIC GROUPS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEALTHCARE DISPARITIES; HISPANIC AMERICANS; HUMANS; HYPERTENSION; MALE; MEDICATION ADHERENCE; MEMANTINE; PREVALENCE; VETERANS;

EID: 60349098930     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1L368     Document Type: Article

References (46)

1. Lloyd-Jones DM, Evans JC, Levy D. Hypertension in adults across the age spectrum: current outcomes and control in the community. JAMA 2005;294:466-72.
2. Ferri CP, Prince M, Brayne C, et al. Alzheimer's disease international. Global prevalence of dementia: a Delphi consensus study. Lancet 2005;366:2112-7.
3. World Health Organization. World health report 2006 - working together for health. www.who.int/whr/2006/en/index.html (accessed 2008 May 20).
4. Schneider J, Murray J, Banergee S, Mann A. EUROCARE: a cross-national study of co-resident spouse carers of people with Alzheimer's disease. Int J Geriatr Psychiatry 1999;14:651-61.
5. Prince M, 10/66 Dementia Research Group. Care arrangements for people with dementia in developing countries. Int J Geriatr Psychiatry 2004;19:170-7.
6. Langa KM, Chernew ME, Kabeto MU, et al. National estimates of the quantity and cost of informal caregiving for the elderly with dementia. J Gen Intern Med 2001;16:770-8.
7. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-52.
8. Beckett NS, Peters R, Fletcher AE. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008;358:1887-98.
9. Elias ME, Wolf PA, D'Agostino RB. Untreated blood pressure level is inversely related to cognitive functioning: the Framingham Study. Am J Epidemiol 1993;138:353-64.
10. Hofman A, Ott A, Breteler MMB, et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 1997;349:151-4.
11. Kivipelto M, Helkala EL, Laakso MP, et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 2001;322:1447-51.
12. Farmer ME, White LR, Abbott RD, et al. Blood pressure and cognitive performance. The Framingham Study. Am J Epidemiol 1987;126:1103-14.
13. Skoog I, Lernfelt B, Landahl S. A 15-year longitudinal study of blood pressure and dementia. Lancet 1996;347:1141-5.
14. Kilander L, Nyman H, Boberg M. Hypertension is related to cognitive impairment: a 20-year follow-up study of 999 men. Hypertension 1998;31:780-6.
15. Launer LJ, Ross GW, Perovich H, et al. Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging 2000;21:49-55.
16. Korf ESC, White LR, Scheltens P, Launer LJ. Midlife blood pressure and the risk for hippocampal atrophy: the Honolulu Asia Aging Study. Hypertension 2004;44:29-34.
17. Khachaturian AS, Zandi PP, Lyketsos CG, et al. Antihypertensive medication use and incident Alzheimer disease: the Cache County Study. Arch Neurol 2006;63:686-92.
18. Guo Z, Fratiglioni L, Zhu L, Fastbom J, Winblad B, Viitanen M. Occurrence and progression of dementia in a community population aged 75 years and older: relationship of antihypertensive medication use. Arch Neurol 1999;56:991-6.
19. Murray MD, Lane KA, Evans RM, Unverzagt FW, Hall KS, Hendrie MB. Preservation of cognitive function with antihypertensive medications: a longitudinal analysis of a community-based sample of African Americans. Arch Intern Med 2002;162:2090-6.
20. Peila R, White LR, Masaki K, Petrovitch H, Launer LJ. Reducing the risk of dementia: efficacy of long-term treatment of hypertension. Stroke 2006;37:1165-70.
21. Forette F, Seux ML, Staessen JA, Thijs L, Birkenhager WH. Reduction of dementia by calcium-antagonist-based antihypertensive treatment. Eur Heart J 2000;2:D17-9.
22. Forette F, Seux ML, Staessen JA, et al. Prevention of dementia in randomised double-blind placebo-controlled systolic hypertension in Europe (Syst-Eur) Trial. Lancet 1998;352:1347-51.
23. Forette F, Seux M-L, Staessen JA, et al. The prevention of dementia with antihypertensive treatment. New evidence from the systolic hypertension in Europe (Syst-Eur) Study. Arch Intern Med 2002;162:2046-52.
24. The PROGRESS Collaborative Group. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 2003;163:1069-75.
25. Giles T, Aranda JM, Suh DC, et al. Ethnic/racial variations in blood pressure awareness, treatment, and control. J Clin Hypertens (Greenwich) 2007;9:345-54.
26. Ostchega Y, Dillon CF, Hughes JP, Carroll M, Yoon S. Trends in hypertension prevalence, awareness, treatment, and control in older US adults: data from the National Health and Nutrition Examination Survey 1988 to 2004. J Am Geriatr Soc 2007;55:1056-65.
27. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment and control of hypertension in the United States, 1988-2000. JAMA 2003;290:199-206.
28. Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) 2002;4:393-404.
29. Siegel D, Lopez J, Meier J. Antihypertensive medication adherence in the Department of Veterans Affairs. Am J Med 2007;120:26-32.
30. Wong MD, Shapiro MF, Boscardin WJ, Ettner SL. Contribution of major diseases to disparities in mortality. N Eng J Med 2002;347:1585-92.
31. Tang MX, Cross P, Andrews H, et al. Incidence of AD in African Americans, Caribbean Hispanics, and Caucasians in northern Manhattan. Neurology 2001;56:49-56.
32. Husaini BA, Sherkat DE, Moonis M, Levine R, Holzer C, Cain VA. Racial differences in the diagnosis of dementia and in its effects on the use and costs of health care services. Psychiatr Serv 2003;54:92-6.
33. Poon IO, Lal LS, Ford ME, Braun U. Race/ethnicity differences in utilization of antihypertensive medications in elderly veterans with dementia. Presented at: American Society of Health-System Pharmacists Midyear Clinical Meeting, Las Vegas, NV, December 4, 2007.
34. Johnson ML, Singh H. Patterns of antihypertensive therapy among patients with diabetes. J Gen Intern Med 2005;20:842-6.
35. Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother 2006;40:1280-8. Epub 25 Jul 2006. DOI 10.1345/aph.1H018
36. Doody RS, Stevens JC, Beck C, et al. Practice parameter: management of dementia (an evidence-based review). Report of the quality standards subcommittee of the American Academy of Neurology. Neurology 2001;56:1154-66.
37. Wilkinson D, Doody R, Helme R, et al. Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology 2003;61:479-86.
38. Roberts JS, Connell CM, Cisewski D, Hipps YG, Demissie S, Green RC. Differences between African Americans and whites in their perceptions of Alzheimer disease. Alzheimer Dis Assoc Disord 2003;17:19-26.
39. Street RL, O'Malley KJ, Cooper LA, Haidet P. Understanding concordance in patient-physician relationships: personal and ethnic dimensions of shared identity. Ann Fam Med 2008;6:198-205.
40. Bosworth HB, Dudley T, Olsen MK, et al. Racial differences in blood pressure control: potential explanation factors. Am J Med 2006;119:70.e9-15.
41. Howard G, Prineas R, Moy C, et al. Racial and geographic differences in awareness, treatment, and control of hypertension: the reasons for geographic and racial differences in stroke study. Stroke 2006;37:1171-8.
42. Safford MM, Halanych JH, Lewis CE, Levine D, Houser S, Howard G. Understanding racial disparities in hypertension control: intensity of hypertension medication treatment in the REGARDS study. Ethn Dis 2007;17:421-6.
43. Goldstein FC, Ashley AV, Freedman LJ, et al. Hypertension and cognitive performance in African Americans with Alzheimer disease. Neurology 2005;64:899-901.
44. Hargrave R. AGS Position Paper: Caregivers of African-American elderly with dementia: a review and analysis. Ann Long-Term Care 2006;14(10):36-40.
45. Diaz E, Woods SW, Rosenheck RA. Effects of ethnicity on psychotropic medications adherence. Community Ment Health J 2005;41:521-37.
46. Gellad WF, Haas JS, Safran DG. Race/ethnicity and nonadherence to prescription medications among seniors: results of a national study. J Gen Intern Med 2007;22:1572-8.